FDA clears ultrasonic surgical aspiration tech for cardiac surgery
The CUSA Clarity Ultrasonic Surgical Aspirator System from New Jersey-based Integra LifeSciences has been cleared by the U.S. Food and Drug Administration (FDA) to be used during cardiac surgeries such as valve repairs and replacements.
The device was previously cleared to help remove unwanted tissue during neurosurgery, plastic and reconstructive surgery, orthopedic surgery, gynecological surgery, thoracic surgery and laparoscopic surgery.
The CUSA Clarity Ultrasonic Surgical Aspirator System was developed to provide assistance when surgeons need soft and hard tissue fragmented, emulsified, aspirated or otherwise managed. It includes one lightweight handpiece that uses ultra-high frequency vibrations, and a separate handpiece that comes with an optional electrosurgical attachment. The console, meanwhile, includes an interactive touchscreen that helps users setup the equipment.
“The utilization of CUSA Clarity for cardiac surgery marks the next pivotal expansion of the ultrasonic surgical aspirator system’s breadth of indications,” Mike McBreen, executive vice president and president of Integra’s Codman Specialty Surgical division, said in a statement. “As one of the leaders in the industry, this milestone strengthens our ability to deliver advanced surgical solutions to support restoring patients’ lives.”
To help introduce this technology to the cardiac surgery audience, Integra LifeSciences will be highlighting its potential benefits during the American Association for Thoracic Surgery Mitral Valve Conclave in New York City Dec. 11-12.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.